
Traws Pharma, Inc. — Investor Relations & Filings
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral small-molecule therapies for respiratory viral diseases. The company focuses on advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains. Its pipeline includes two lead candidates: ratutrelvir, a ritonavir-independent antiviral targeting the Main protease (Mpro) for the treatment of COVID-19 and Long COVID, and tivoxavir marboxil, a single-dose antiviral targeting the influenza cap-dependent endonuclease (CEN) for the treatment and prevention of bird flu and seasonal influenza. The company aims to develop safe product candidates with simple dosing regimens.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B5 | 2026-05-22 | English | |
| 424B3 | 2026-05-15 | English | |
| 10-Q | 2026-05-15 | English | |
| FORM 8-K | 2026-05-15 | English | |
| S-3 - Traws Pharma, Inc. (0001130598) (Filer) | 2026-05-08 | English | |
| 10-K - Traws Pharma, Inc. (0001130598) (Filer) | 2026-04-15 | English |
Browse filings by year
23 years- 2026 14 filings
- 2025 92 filings
- 2024 73 filings
- 2023 40 filings
- 2022 39 filings
- 2021 79 filings
- 2020 70 filings
- 2019 99 filings
- 2018 99 filings
- 2017 47 filings
- 2016 88 filings
- 2015 52 filings
- 2014 40 filings
- 2013 76 filings
- 2012 3 filings
- 2011 1 filing
- 2010 2 filings
- 2009 1 filing
- 2007 2 filings
- 2006 2 filings
- 2005 2 filings
- 2004 2 filings
- 2003 4 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 46816511 | 424B5 | 2026-05-22 | English | ||
| 46363212 | 424B3 | 2026-05-15 | English | ||
| 46352924 | 10-Q | 2026-05-15 | English | ||
| 46352907 | FORM 8-K | 2026-05-15 | English | ||
| 44433492 | S-3 - Traws Pharma, Inc. (0001130598) (Filer) | 2026-05-08 | English | ||
| 34610821 | 10-K - Traws Pharma, Inc. (0001130598) (Filer) | 2026-04-15 | English | ||
| 34609866 | 8-K - Traws Pharma, Inc. (0001130598) (Filer) | 2026-04-15 | English | ||
| 34577213 | 8-K - Traws Pharma, Inc. (0001130598) (Filer) | 2026-04-15 | English | ||
| 32888113 | 8-K - TRAWS PHARMA, INC. (0001130598) (Filer) | 2026-02-19 | English | ||
| 28061771 | SCHEDULE 13G Filing | 2026-02-12 | English | ||
| 28061907 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 28061817 | 8-K Filing | 2026-01-26 | English | ||
| 28061781 | SCHEDULE 13G Filing | 2026-01-16 | English | ||
| 28061770 | 8-K Filing | 2026-01-13 | English | ||
|
2025
1 filing
| |||||
| 11410466 | FORM 8-K | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Traws Pharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35199/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35199 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35199 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35199 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35199}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Traws Pharma, Inc. (id: 35199)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.